Edition:
India

Manas Mishra

Moderna rally loses steam over COVID-19 vaccine worries

28 May 2020

Shares of biotechs racing to make coronavirus vaccines, including Moderna Inc , fell about 10% on Wednesday, as investor concerns grew about the prospects of the experimental products that are still in early stages of development.

Moderna rally loses steam over COVID-19 vaccine worries

28 May 2020

May 27 Shares of biotechs racing to make coronavirus vaccines, including Moderna Inc, fell about 10% on Wednesday, as investor concerns grew about the prospects of the experimental products that are still in early stages of development.

GSK ties up with gene editing start-up Mammoth for COVID-19 test

20 May 2020

By Manas Mishra GlaxoSmithKline's consumer health unit has tied up with Mammoth Biosciences to develop a test that uses a technology commonly used in gene editing to detect novel coronavirus infections, the California-based startup said on Wednesday.

GSK ties up with gene editing start-up Mammoth for COVID-19 test

20 May 2020

GlaxoSmithKline's consumer health unit has tied up with Mammoth Biosciences to develop a test that uses a technology commonly used in gene editing to detect novel coronavirus infections, the California-based startup said on Wednesday.

FDA approves Bristol-Myers combo therapy for lung cancer

16 May 2020

The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb Co's combination therapy for previously untreated patients with a form of lung cancer, a much-needed boost as the company battles the dominance of Merck's Keytruda.

FDA approves Eli Lilly drug for thyroid, lung cancers driven by a genetic mutation

09 May 2020

The U.S. Food and Drug Administration on Friday approved a drug to treat lung and thyroid cancers driven by a specific genetic mutation that Eli Lilly and Co acquired with its 2019 purchase of Loxo Oncology.

UPDATE 2-Novartis prices lung cancer drug at $17,950 for 28-day supply

07 May 2020

May 6 Novartis AG on Wednesday priced its treatment for a hard-to-treat form of lung cancer at the U.S. wholesale acquisition cost of $17,950 for a 28-day supply, following the drug's approval by regulators.

CVS Health maintains 2020 profit forecast despite coronavirus hit

06 May 2020

CVS Health Corp on Wednesday said it was sticking to its 2020 forecast and expected a strong second quarter, as reduced medical service use for its Aetna insurance business offset coronavirus-related expenses and the pandemic's impact on pharmacy sales and prescriptions.

Alexion bets on Portola's bleeding antidote with $1.41 billion deal

05 May 2020

Alexion Pharmaceuticals Inc on Tuesday agreed to buy Portola Pharmaceuticals Inc in a $1.41 billion deal, as it looks to exploit smaller rival's blood-thinning antidote which has reached only a tiny portion of its target population.

AbbVie sees substantial hit to Botox from pandemic, lowers Humira growth forecast

01 May 2020

AbbVie Inc on Friday said it expects the coronavirus outbreak to substantially limit sales of Botox and similar aesthetic products that the U.S. drugmaker is set to acquire through its buyout of Allergan Plc .

World News